🇺🇸

US SEC Filing Intelligence

· daily

US Corporate Distress Financial Stress SEC Filings — July 24, 2026

This digest captures a severe wave of corporate distress across 18 US-listed companies, predominantly driven by Nasdaq and NYSE minimum bid price and market value deficiencies. The most critical development is the confirmed Chapter 11 plan for QVC Inc. and QVC Group, where all existing equity will be canceled for no consideration, representing a total loss for shareholders. A staggering 14 out of 18 filings involve delisting or non-compliance notices, with 12 specifically for sub-$1.00 bid prices, indicating a systemic liquidity and valuation crisis among small-cap and micro-cap names. The biotech and tech sectors are disproportionately affected, with 6 biotech/life sciences firms and 4 tech companies facing imminent listing threats. Insider activity data is sparse, but the absence of insider buying in the face of these distress signals is a notable bearish indicator. The QVC bankruptcy is the highest materiality event (10/10), while the cluster of bid price deficiencies creates a calendar of critical compliance deadlines between July 2026 and January 2027.

18 high priority 18 total filings
· daily

Global High-Priority Regulatory Events — July 24, 2026

The July 24, 2026 digest reveals a market bifurcated between aggressive capital deployment and acute financial distress. A wave of M&A and strategic investments—including Berkshire Hathaway's $8.5B acquisition of Taylor Morrison and a $240M PIPE for Freenome—signals strong corporate confidence in specific sectors. However, this is contrasted by a deluge of Nasdaq delisting warnings (11 filings) and a major retail bankruptcy (QVC), indicating severe stress among smaller and leveraged companies. Period-over-period data shows strong revenue growth at Apar Industries (+29.1% YoY) and Welspun Corp (+14.9% YoY), but also significant profit declines at ACC Limited (-61.6% YoY). The most critical development is the QVC Chapter 11 confirmation, which will wipe out all equity holders, serving as a stark warning for holders of distressed retail debt. The dominant theme is a 'survival of the fittest' environment where well-capitalized firms are consolidating, while those with weak balance sheets or market valuations are being purged from public markets.

50 high priority 50 total filings
· daily

US SEC Filings Daily Market Digest — July 24, 2026

Today's digest reveals a market bifurcated between aggressive capital deployment through M&A and buybacks, and significant financial distress at the micro-cap level. The most critical development is Intel's staggering $11.0B quarterly net loss, driven by a $13.6B non-cash mark-to-market charge, which overshadows its strong 25% revenue growth and gross margin improvement. In the energy sector, a major consolidation is underway with MN8 Energy's acquisition of Greenbacker, creating a top-three clean power platform. The financial sector shows mixed signals, with Flagstar Bank posting improved earnings but rising credit costs, while Woori Financial pursues an aggressive expansion strategy. Insider selling at Sea Ltd. and ASE Technology, coupled with a major insider exit filing for Upexi, signals caution in tech. Conversely, the capital allocation theme is strong, with News Corp authorizing a $1B buyback, Flagstar announcing a $250M repurchase program, and multiple companies declaring dividends. The SPAC and biotech space is active, with Perceptive Capital Solutions completing its merger with Freenome and SoundHound AI clearing final regulatory hurdles for its LivePerson acquisition. A clear theme of 'haves and have-nots' emerges, with strong balance sheets funding growth and buybacks, while cash-strapped entities like Atlantis Glory and Versus Systems face existential risks.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — July 24, 2026

Las Vegas Sands Corp. (LVS) reported mixed Q2 2026 results that reveal a bifurcated performance between the quarter and the first half of the year. While Q2 net revenues slipped 0.7% YoY to $3.154B and net income plunged 25% to $346M, the first half of 2026 tells a more bullish story with revenues up 11.6% to $6.739B and net income rising 12.3% to $913M. The company continues to aggressively return capital to shareholders, deploying $1.942B in buybacks and dividends in H1 2026, signaling strong management confidence despite the quarterly earnings miss. A critical red flag is the tripling of provision for credit losses to $65M in H1 2026 from $21M a year ago, suggesting deteriorating customer credit quality in Macau or Singapore. However, operating cash flow nearly doubled to $1.413B in H1 2026, providing ample liquidity to support both debt reduction (total debt down $962M to $13.694B) and shareholder returns. The mixed sentiment rating of 9/10 materiality reflects the tension between strong cash generation and capital returns versus the concerning credit loss trend and quarterly earnings decline.

1 high priority 1 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — July 24, 2026

The sole filing for the S&P 500 Healthcare sector on July 24, 2026, is a routine Schedule 13G/A from Baillie Gifford & Co regarding its passive stake in Moderna, Inc. The filing reveals a slight increase in absolute share count (from 17.92M to 18.21M shares) but a marginal decrease in ownership percentage (from 4.6% to 4.59%), likely due to share dilution or share repurchases by Moderna. The filing carries neutral sentiment and low materiality (3/10), indicating no change in control intent or activist pressure. With only one filing and no period-over-period financial comparisons, insider transactions, forward-looking guidance, or capital allocation data available, the digest is necessarily limited in breadth. However, the passive nature of this filing and the stable, large stake suggest continued institutional confidence in Moderna's long-term prospects, even as the broader healthcare sector faces headwinds from regulatory and pricing pressures.

1 medium 1 total filings
· daily

US Earnings Financial Results SEC Filings — July 24, 2026

The 44 filings for the period ending July 24, 2026, reveal a market characterized by a strong cyclical recovery in industrials and materials, with Dow Inc., Halliburton, and J.B. Hunt posting significant YoY revenue and profit improvements. However, this is juxtaposed against severe distress in several pre-revenue SPACs and cash-burning tech companies like Atlantis Glory and BTCS Labs, which face existential liquidity risks. A notable sector divergence is emerging in the semiconductor space, where Texas Instruments and TE Connectivity show robust double-digit growth, while Intel's core business improves but is massively distorted by a $13.6B non-cash charge on escrowed shares. The insurance sector (RLI, Selective) is a standout for consistent earnings growth, driven by higher premiums and investment income. A critical portfolio-level trend is the aggressive use of share buybacks by Charter Communications, SkyWest, and Las Vegas Sands to boost EPS, masking underlying revenue or profit weakness. Insider trading data is sparse, but the absence of insider buying in troubled companies like GrafTech and Noodles & Co is a notable negative signal. The most critical development is the widening gap between operational performance and bottom-line results, driven by non-operating charges, restructuring costs, and tax adjustments, requiring investors to look past headline net income.

44 high priority 44 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 24, 2026

The 12 filings reveal a bifurcated landscape: established industrial and tech firms like RBC Bearings and Deckers Outdoor are delivering strong operational performance with robust revenue growth (14.3% and 9.8% YoY, respectively), while micro-cap companies like NanoVibronix and Knightscope face existential risks, including Nasdaq delisting and shareholder dilution. Governance changes are a key theme, with Deckers appointing a new Board Chair and RBC Bearings reducing board size amid an aging CEO (81), signaling potential succession planning. Insider activity is notably absent across most filings, but the heavy use of equity incentives (e.g., RBC Bearings' CEO achieving 113.5% of target) suggests strong alignment with shareholder value. Capital allocation trends vary: RBC Bearings uses free cash flow for debt reduction and M&A, while ePlus is restructuring post-divestiture. The most critical development is NanoVibronix's reverse stock split proposal (1:2 to 1:50) to regain Nasdaq compliance, a high-risk move with no long-term price guarantee. Portfolio-level patterns highlight a 'growth vs. survival' divide, with mid-cap firms leveraging operational excellence and micro-caps struggling with liquidity and compliance.

12 high priority 12 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 24, 2026

The IPO pipeline on July 24, 2026, is dominated by two $150 million SPAC IPOs (Bluerock Acquisition Corp. II and K2 Capital Acquisition Corp. II) and three smaller, higher-risk operating company registrations (INVO Fertility, Powerdyne International, and Isabella Bank Corp's S-4 merger proxy). A key theme is the resurgence of blank-check companies, with two SPACs filing on the same day, signaling renewed sponsor confidence in the SPAC market after a prolonged downturn. However, the quality of the non-SPAC filers is mixed: INVO Fertility shows signs of operational distress (regaining compliance after late filings, a reverse stock split, and a dilutive resale offering), while Powerdyne International acknowledges material weaknesses in internal controls, a major red flag for new public investors. The Isabella Bank S-4 is a merger proxy, not a capital raise, and is the only filing with a clear, near-term catalyst (a shareholder vote). No period-over-period financial trends are available as all companies are pre-revenue or newly public, shifting the focus to governance, dilution risk, and deal structure. The most critical development is the simultaneous SPAC filings, which may indicate a broader market appetite for blank-check vehicles, but investors must scrutinize the lack of identified targets and the potential for dilution.

5 high priority 5 total filings
· daily

USA Institutional Investor Activity — July 24, 2026

The sole filing in this intelligence stream is a 13F-HR from Charter Capital Management, LLC, covering its equity and ETF holdings as of June 30, 2026. The filing reveals a portfolio concentrated in broad-based ETFs (iShares Core S&P Mid-Cap, Vanguard S&P 500) and mega-cap single stocks (Apple, Microsoft, Berkshire Hathaway, Nvidia). Without market values or prior-period share counts in the provided excerpt, no period-over-period position changes or dollar-weighted trends can be calculated, resulting in a neutral/mixed sentiment. The filing provides no forward-looking guidance, insider trading activity, capital allocation actions, or transaction details, limiting actionable signals. The key takeaway is the firm's passive/index-oriented core strategy with selective large-cap equity bets, suggesting a stable, long-term positioning rather than active tactical shifts. No sector-level themes or cross-filing comparisons are possible with a single filing.

1 medium 1 total filings
· daily

US SEC Trading Suspension Halt Orders — July 24, 2026

On July 24, 2026, a wave of 16 regulatory filings revealed a surge in trading suspension and delisting risks across US-listed companies, predominantly driven by non-compliance with Nasdaq's $1.00 minimum bid price rule. A staggering 13 of 16 filings involve bid price deficiencies, with several companies receiving their second notice within a year, indicating a systemic failure to maintain share price thresholds. The cluster of filings on a single day suggests a coordinated exchange review cycle, creating a concentrated risk event for investors holding these securities. While most companies have 180-day cure periods, the high recurrence rate and ineligibility for extensions due to prior reverse splits (e.g., FibroBiologics) signal a 'penalty box' dynamic where serial non-compliers face accelerated delisting. The only voluntary delisting (Trinity Capital) and the sole equity-based deficiency (VivoSim Labs) stand as outliers, highlighting that the primary systemic risk is price-driven, not fundamental. The lack of any bullish or positive insider activity across all filings reinforces a uniformly negative sentiment, with management teams scrambling for reverse splits as a last-resort remedy.

16 high priority 16 total filings
· daily

US Executive Officer Management Changes SEC — July 24, 2026

This intelligence digest analyzes 39 regulatory filings from July 24, 2026, focused on US executive and director changes. The most critical development is the resignation of Microchip Technology's COO without a named successor, creating a leadership vacuum in a key operational role. A notable trend is the significant shareholder dissent at Constellation Brands' annual meeting, with over 11% of votes against the Sands family directors, signaling governance concerns. The period-over-period data from ChoiceOne Financial Services reveals a mixed operating environment, with core loan growth of 11.9% annualized offset by margin compression from reduced purchase loan accretion. Several companies are deploying retention-based equity awards, including L3Harris ($25M), Corpay (300,000 PSUs to CEO), and NN Inc., indicating a competitive market for top executive talent. The appointment of Celso Goncalves as President of Cleveland-Cliffs, while also being the son of the CEO, raises corporate governance questions despite the positive signal of internal succession planning. Overall, the filings suggest a market where companies are actively managing leadership transitions and using equity incentives to retain key personnel amid a challenging macroeconomic backdrop.

39 high priority 39 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — July 24, 2026

Both filings concern the same bankruptcy event: QVC Inc. and its parent QVC Group Inc. received court confirmation of their prepackaged Chapter 11 plan on July 20, 2026. The plan wipes out all existing equity (common and preferred) for zero consideration, while secured noteholders receive new equity, cash, and takeback debt. Trade and unsecured claims are to be paid in full, and the company expects to emerge from bankruptcy after satisfying conditions precedent. The filings are materially identical, with QVC Group's 8-K adding detail on the issuance of 50 million new common shares. The negative sentiment and maximum materiality (10/10) reflect a total loss for equity holders but a structured recovery for creditors, signaling a high-risk, high-conviction restructuring event.

2 high priority 2 total filings
· daily

US Corporate Board Director Changes SEC Filings — July 24, 2026

This intelligence stream covers 38 regulatory filings from July 24, 2026, focused on board room changes including officer appointments, resignations, and compensation adjustments. Key themes include a wave of insider equity grants and retention awards designed to lock in top talent, particularly in the industrial and technology sectors, alongside several notable CEO and CFO succession events. A significant pattern is the use of performance-based equity with specific stock price hurdles (e.g., Corpay, AAR Corp) and retention packages tied to FDA approval milestones (Outlook Therapeutics). While most changes are routine, several high-materiality events stand out: the resignation of Microchip Technology's COO to become a CEO elsewhere, a succession plan at Cleveland-Cliffs promoting the founder's son, and a special $25M retention award at L3Harris. The aggregate data reveals a strong emphasis on aligning executive compensation with shareholder value creation, with a notable uptick in insider equity grants as a retention tool rather than cash bonuses.

38 high priority 38 total filings
· daily

USA Insider Trading Pulse — July 24, 2026

The July 24, 2026 insider trading pulse reveals a market characterized by significant insider selling at the C-suite level, particularly in technology and financial services, with several high-value transactions executed under 10b5-1 plans. Notable insider buying is concentrated in small-cap and micro-cap names, suggesting selective value-seeking by management. A key theme is the prevalence of option exercises paired with immediate sales, indicating compensation harvesting rather than outright bearish conviction. The data also shows a wave of stock awards across multiple companies, signaling ongoing equity-based compensation programs. The most material signals include a large-scale sale by a PG&E insider, a significant sell-off by a Travelers executive, and a substantial insider purchase in a small-cap biotech, creating a bifurcated landscape of risk and opportunity.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 24, 2026

The July 24, 2026, M&A digest reveals a bifurcated market: large-cap strategic acquisitions (Berkshire Hathaway/Taylor Morrison) and SPAC-driven deals (Perceptive/Freenome) dominate headline materiality, while a wave of early-stage SPACs (AMR Resources, Range Capital) signal continued appetite for mineral resources and tactical targets. Period-over-period comparisons from the enriched data show a clear trend of cash-rich acquirers deploying capital into high-growth but cash-burning assets (Freenome's $1.45B accumulated deficit) and established homebuilding platforms (Taylor Morrison's 23,000 closings). Insider activity is muted across the SPAC cohort, but the Freenome PIPE ($240M) and Roche convertible note conversion indicate strong institutional conviction. A key outlier is KULR Technology, which sold 30% of its bitcoin holdings to deleverage, a defensive capital allocation move that contrasts with the broader M&A spending spree. The most critical development is the Taylor Morrison acquisition at a 10/10 materiality, which reshapes the US homebuilding landscape and signals Berkshire's aggressive push into vertically integrated housing.

7 high priority 7 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 24, 2026

The overnight filing period from July 23-24, 2026, reveals a market dominated by transformative M&A activity, mixed earnings results, and significant insider selling. The most critical development is the creation of a top-three U.S. clean power platform via the Greenbacker/MN8 merger ($375M base purchase price, ~6.2 GW combined capacity), alongside SoundHound AI clearing all foreign regulatory hurdles for its LivePerson acquisition. Financial sector results are bifurcated: Flagstar Bank showed a dramatic YoY earnings turnaround (net income of $26M vs. a $78M loss), while Woori Financial posted strong QoQ net income growth (+60.5%) but declining revenue (-13.9% QoQ). A notable pattern of insider selling emerged, with executives at Cadence Design Systems, Viant Technology, and Kaspi.kz all executing pre-planned sales. Intel's Q2 results present a stark contrast: revenue grew 25% YoY to $16.1B and gross margins improved to 40.4%, but a massive $13.6B mark-to-market loss on escrowed shares drove a net loss of $11.0B, widening from a $2.9B loss a year ago. The period also saw two significant SPAC combinations close (Perceptive Capital/Freenome with $332.6M pro forma cash) and a major debt offering from Galaxy Digital ($3.5B in senior secured notes).

24 high priority 26 medium 50 total filings
· daily

Biotech Small-Cap Approvals — July 23, 2026

The July 23, 2026 digest covers two biosimilar approvals from small-cap sponsors, DR REDDYS LABS LTD for SITAGLIPTIN PHOSPHATE and RISING for HYDROCORTISONE, with no NMEs, biosimilars, or label expansions recorded. Both approvals are classified as FALLBACK type with neutral signals, indicating limited immediate investment impact. The absence of NMEs or breakthrough designations suggests a quiet period for high-value catalysts, while the biosimilar entries may pressure originator market shares in diabetes and corticosteroid segments. Key risk is the lack of commercial detail (peak sales, exclusivity, pricing) for both drugs, making revenue projections uncertain. The highest-conviction signal is the neutral rating on both approvals, reflecting low materiality for institutional portfolios.

2 total filings
· daily

Big Pharma Approvals — July 23, 2026

The July 23, 2026 approval period featured a single label expansion for Novartis' IPTACOPAN HYDROCHLORIDE (FABHALTA), classified as a 'Fallback' approval with a bullish signal. This is a low-volume period with zero NMEs, biosimilars, or standard label expansions, limiting sector-wide thematic signals. The highest-conviction signal is the Fabhalta label expansion, which strengthens Novartis' position in complement-mediated diseases but carries modest materiality given undisclosed peak sales and exclusivity details. The key risk is the lack of clarity on the specific indication and competitive dynamics, making this a watch-and-confirm event rather than a high-impact catalyst.

1 total filings